Encephalomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22103IDB-ST

Select Item

Encephalomyelitis pipeline market research report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.

Key Targets in the Encephalomyelitis Pipeline Market

The key targets in the encephalomyelitis pipeline market are Sodium Dependent Dopamine Transporter, Corticotropin Releasing Factor Receptor 2, DNA Polymerase, Interleukin 10, NACHT LRR And PYD Domains Containing Protein 3, Neurotrophin 3, Nuclear Factor Erythroid 2 Related Factor 2. Sodium Dependent Dopamine Transporter has the highest number of pipeline products.

Encephalomyelitis Pipeline Market, by Targets

Encephalomyelitis Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Encephalomyelitis Pipeline Market

The key MoA in the encephalomyelitis pipeline market are Sodium Dependent Dopamine Transporter Inhibitor, Corticotropin Releasing Factor Receptor 2 Agonist, DNA Polymerase Inhibitor, Interleukin 10 Activator, Neurotrophin 3 Activator, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor. Sodium Dependent Dopamine Transporter Inhibitor has the highest number of pipeline products.

Encephalomyelitis Pipeline Market, by MoA

Encephalomyelitis Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Encephalomyelitis Pipeline Market

The key RoA in the encephalomyelitis pipeline market are oral, intravenous, intraperitoneal, intravitreal, nasal, and subcutaneous. Oral has the highest number of pipeline market.

Encephalomyelitis Pipeline Market, by RoA

Encephalomyelitis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Encephalomyelitis Pipeline Market

The key molecule types in the encephalomyelitis pipeline market are small molecule, gene-modified cell therapy, oligonucleotide, peptide, protein, and synthetic peptide. Small molecule has the highest number of pipeline products.

Encephalomyelitis Pipeline Market, by Molecule Types

Encephalomyelitis Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Encephalomyelitis Pipeline Market

The key companies in the encephalomyelitis pipeline market are AIM ImmunoTech Inc, Biovista Inc, Cortene Inc, F. Hoffmann-La Roche Ltd, K-Pax Pharmaceuticals Inc, NLS Pharmaceutics AG, Orion BioScience Inc, Paxmedica Inc, Telesphore Pharma, Trethera Corp, and Virios Therapeutics Inc.

Market report overview

Key targets Sodium Dependent Dopamine Transporter, Corticotropin Releasing Factor Receptor 2, DNA Polymerase, Interleukin 10, NACHT LRR And PYD Domains Containing Protein 3, Neurotrophin 3, and  Nuclear Factor Erythroid 2 Related Factor 2
Key MoA Sodium Dependent Dopamine Transporter Inhibitor, Corticotropin Releasing Factor Receptor 2 Agonist, DNA Polymerase Inhibitor, Interleukin 10 Activator, Neurotrophin 3 Activator, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor
Key RoA Oral, Intravenous, Intraperitoneal, Intravitreal, Nasal, and Subcutaneous
Key molecule types Small Molecule, Gene-Modified Cell Therapy, Oligonucleotide, Peptide, Protein, and Synthetic Peptide
Key companies AIM ImmunoTech Inc, Biovista Inc, Cortene Inc, F. Hoffmann-La Roche Ltd, K-Pax Pharmaceuticals Inc, NLS Pharmaceutics AG, Orion BioScience Inc, Paxmedica Inc, Telesphore Pharma, Trethera Corp, and Virios Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
F. Hoffmann-La Roche Ltd
K-Pax Pharmaceuticals Inc
NLS Pharmaceutics AG
Orion BioScience Inc
Paxmedica Inc
Telesphore Pharma
Trethera Corp
Virios Therapeutics, Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Encephalomyelitis – Overview

Encephalomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Encephalomyelitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalomyelitis – Companies Involved in Therapeutics Development

AIM ImmunoTech Inc

Biovista Inc

Cortene Inc

F. Hoffmann-La Roche Ltd

K-Pax Pharmaceuticals Inc

NLS Pharmaceutics AG

Orion BioScience Inc

Paxmedica Inc

Telesphore Pharma

Trethera Corp

Virios Therapeutics, Inc

Encephalomyelitis – Drug Profiles

(celecoxib + famciclovir) – Drug Profile

Product Description

Mechanism Of Action

CADIT-1031 – Drug Profile

Product Description

Mechanism Of Action

CT-38 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

JM-4 – Drug Profile

Product Description

Mechanism Of Action

KPAX-002 – Drug Profile

Product Description

Mechanism Of Action

MCC-950 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NLS-4 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ORNx-KI – Drug Profile

Product Description

Mechanism Of Action

History of Events

PAX-101 – Drug Profile

Product Description

Mechanism Of Action

rintatolimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Chronic Fatigue Syndrome – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Encephalomyelitis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology – Drug Profile

Product Description

Mechanism Of Action

WEHI-345 – Drug Profile

Product Description

Mechanism Of Action

Encephalomyelitis – Dormant Projects

Encephalomyelitis – Product Development Milestones

Featured News & Press Releases

Nov 30, 2021: NLS Pharmaceutics announces preclinical results confirming the potential benefit and safety profile of NLS-4 for circadian rhythm dysregulation and chronic fatigue syndrome in long-covid model

Oct 14, 2021: NLS Pharmaceutics announces preclinical data demonstrating the potential of NLS-4 (Lauflumide) to treat chronic fatigue associated with long-covid

Jan 07, 2021: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection

Dec 24, 2020: AIM ImmunoTech announces availability of the ME/CFS clinical trial of its drug Ampligen for enrollment to COVID-19 ‘Long Haulers’

Nov 02, 2020: AIM ImmunoTech announces PLOS ONE’s publication of new data analyses showing importance of disease duration on Ampligen’s positive role in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Oct 06, 2020: AIM ImmunoTech announces IRB approval to enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS clinical trial of Ampligen

Jun 15, 2020: AIM ImmunoTech provides update on commercial launch of Ampligen in Argentina for the treatment of chronic fatigue syndrome

Sep 24, 2019: AIM ImmunoTechs Ampligen receives clearance from FDA for exportation to Argentina for the treatment of severe chronic fatigue syndrome

May 06, 2019: Hemispherx links Stanford’s ME/CFS diagnostic to a potential path forward for Ampligen Commercialization

Jan 24, 2019: Hemispherx Biopharmas CEO to present at the 15th Annual NobleConXV Conference

Jan 02, 2019: Hemispherx Biopharma announces advancement in expanded access program for Ampligen in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Dec 19, 2018: Hemispherx Biopharma announces first large Ampligen shipment to a clinical site for use in U.S. Expanded Access Program

Dec 17, 2018: Hemispherx Biopharma announces updated information about ME/CFS expanded access program in the United States

Oct 22, 2018: Hemispherx Outlines Ampligen combination therapy clinical study strategy for the treatment of multiple cancers in letter to stockholders

Sep 18, 2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Encephalomyelitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Encephalomyelitis – Pipeline by AIM ImmunoTech Inc, 2022

Encephalomyelitis – Pipeline by Biovista Inc, 2022

Encephalomyelitis – Pipeline by Cortene Inc, 2022

Encephalomyelitis – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Encephalomyelitis – Pipeline by K-Pax Pharmaceuticals Inc, 2022

Encephalomyelitis – Pipeline by NLS Pharmaceutics AG, 2022

Encephalomyelitis – Pipeline by Orion BioScience Inc, 2022

Encephalomyelitis – Pipeline by Paxmedica Inc, 2022

Encephalomyelitis – Pipeline by Telesphore Pharma, 2022

Encephalomyelitis – Pipeline by Trethera Corp, 2022

Encephalomyelitis – Pipeline by Virios Therapeutics, Inc, 2022

Encephalomyelitis – Dormant Projects, 2022

Encephalomyelitis – Dormant Projects, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Encephalomyelitis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Encephalomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Encephalomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Encephalomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more